- The IPO companies concerned in this issue of industrial new shares are: Chengdu Shengnuo Biotechnology Co., Ltd., the place of application for listing is Kechuang board of Shanghai Stock Exchange, the first set of listing standards is selected, the sponsor is Minsheng securities, and the current audit status is “inquired”.
- Its main business is peptide API and generic drug R & D and sales. Six varieties have been activated by FDA
- According to the data released by FDA of the United States, more than 70% of the newly added major peptide generic drug substance DMF were registered in China and India from 2015 to 2019.
- At present, the products of shengnuo biotechnology mainly focus on peptide raw materials and generic drugs.
The IPO companies concerned in this issue of industrial new shares are: Chengdu Shengnuo Biotechnology Co., Ltd., the place of application for listing is Kechuang board of Shanghai Stock Exchange, the first set of listing standards is selected, the sponsor is Minsheng securities, and the current audit status is “inquired”.
No more than 20 million shares are to be issued this time, accounting for no less than 25% of the share capital after the issuance. Wen Yongjun holds 0.29% of the shares of sinobio directly, and Ma lanwen holds 0.25% of the shares of shengnuo biotechnology directly.
Wen and Ma hold 50.00% of the shares ofshengnuo biotechnology indirectly through shengnuo biotechnology investment. The total direct and indirect shareholding ratio is 51.60%. They are the actual controllers of shengnuo biotechnology.
According to the disclosure of Sichuan regulatory bureau, shengnuo biotechnology originally applied for listing on the SME board or gem on June 5, 2019, and then changed to the science and technology innovation board. A week before the opening of the science and technology innovation board, shengnuo biotechnology said that according to the needs of the company’s development, it would be listed on the Shenzhen Stock Exchange gem again. This is the third time that shengnuo biotechnology adjusts its listing board.
Its main business is peptide API and generic drug R & D and sales. Six varieties have been activated by FDA
shengnuo biotechnology’s main business is the R & D, production and sales of peptide preparations and APIs, as well as providing pharmaceutical research and customized production services. Its products cover the fields of immune system diseases, cancer, cardiovascular, chronic hepatitis B, diabetes, AIDS and obstetric diseases.
As of the disclosure date of the prospectus, shengnuo biotechnology has 7 polypeptide preparation products, all of which have obtained domestic approval. Among them, enfoviride for injection and carbetoxine injection are the first imitative polypeptide drugs in China.
shengnuo biotechnology has mastered the large-scale production technology of 15 varieties of API: 7 kinds of polypeptide API production approval documents have been obtained in the domestic market; 8 kinds of DMF activation records in the United States have been obtained in the foreign market.
According to the data released by FDA of the United States, more than 70% of the newly added major peptide generic drug substance DMF were registered in China and India from 2015 to 2019.
According to the data of FDA of the United States in September 2019, among the top 30 polypeptide drugs sold in the world, shengnuo biotechnology has obtained 6 kinds of FDA activation records, ranking the eighth in the world and the third in China.
According to the statistics of QY research, the global peptide drug market scale was about 15.2 billion US dollars in 2010 and 28.5 billion US dollars in 2018, with an annual compound growth rate of 8.17%.
It is estimated that the market size will reach US $49.5 billion in 2027, with an annual compound growth rate of 7.9%.
According to the data released by Zhiyan consulting, the sales volume of polypeptide drugs in China increased from 5.6 billion yuan in 2009 to 29.56 billion yuan in 2017, with an average annual compound growth rate of 23.12%.
At present, the products of shengnuo biotechnology mainly focus on peptide raw materials and generic drugs.
Among them, bevaludine API was registered in DMF of the United States in 2012 and is the first supplier of Fresenius. It is understood that in 2019, the sales volume of bevaludine in the U.S. market is $117 million, with Fresenius accounting for 30.83%.
Carbetoxol was listed in 2016, and the main competitors in the domestic market include Huiling pharmaceutical and Hanyu pharmaceutical. According to the data from the Internet, the domestic market share of shengnuo biotechnology carbetoxine preparations will be 20.97% in 2019. In 2018, atosiban acetate preparation obtained the registration approval and started production and sales.
Domestic market competition enterprises include Huiling pharmaceutical and Hainan Zhonghe. According to the data of the Internet, the domestic market share of atosiban preparation of shengnuo biotechnology acetate is 2.82% in 2019. The domestic market competition of somatostatin preparation, thymopentin raw material drug and new thymus preparation is fierce.
At present, shengnuo biotechnology mainly sells raw material drugs in China, and the main competitive enterprises include suhao Yiming and Suzhou Tianma. In the aspect of octreotide acetate raw materials and preparations, shengnuo biotechnology products were launched late and are still in the market development stage, with a market share of 0.77%.
In addition,shengnuo biotechnology enfoviride API is mainly exported to Mexico, which has not yet been sold in China. Etibante preparation is in the approval stage in China.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……